A real-world study on Senaparib for first-line maintenance treatment in patients with newly diagnosed advanced ovarian cancer,fallopian tube cancer,or primary peritoneal cancer

Status

Recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2600129532

Enrollment

Unknown

Registered

2026-08-06

Start date

2026-04-17

Completion date

Unknown

Last updated

2026-08-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Late-stage ovarian, fallopian tube, or primary peritoneal cancer

Interventions

Senaparib Group:None

Eligibility

Sex/Gender

Female

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Patients newly diagnosed with advanced ovarian cancer, primary peritoneal cancer, or fallopian tube cancer; 2. Patients aged =18 years and <75 years; 3. Patients whom the investigator deems suitable for treatment with the Senaparib regimen; 4. Patients who voluntarily agree to join this study.

Exclusion criteria

Exclusion criteria: 1.Confirmed pregnant or nursing women; 2.Other situations that the researchers deemed unsuitable for inclusion in the study;

Design outcomes

Primary

Measure	Time frame
Progression-free Survival;Overall Survival;	—

Secondary

Measure	Time frame
Severity of Adverse Events;incidence of Adverse Events;	—

Countries

China

Contacts

Public ContactQing Gao

The Second Affiliated Hospital of Xi' an Jiaotong University

dqingao@163.com+86 158 9170 0889

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Aug 25, 2026